Convergence Investment Partners LLC Takes $674,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Convergence Investment Partners LLC bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the third quarter, HoldingsChannel.com reports. The firm bought 1,199 shares of the biopharmaceutical company’s stock, valued at approximately $674,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. CoreCap Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 9.2% in the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock valued at $134,000 after acquiring an additional 20 shares in the last quarter. Strait & Sound Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock worth $353,000 after buying an additional 21 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in Regeneron Pharmaceuticals by 14.8% during the third quarter. Parkside Financial Bank & Trust now owns 163 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 21 shares during the last quarter. Independence Bank of Kentucky increased its position in shares of Regeneron Pharmaceuticals by 7.7% during the 3rd quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 22 shares during the last quarter. Finally, Redwood Wealth Management Group LLC raised its stake in shares of Regeneron Pharmaceuticals by 4.8% during the 2nd quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 23 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan sharply raised its price target to $950 and moved to “overweight,” signaling a sizable upside thesis tied to Regeneron’s recent results and trajectory. Benzinga
• Positive Sentiment: Oppenheimer reaffirmed “outperform” and lifted its target to $865, showing dealer conviction that Q4 results justify higher analyst estimates. Benzinga
• Positive Sentiment: Cantor Fitzgerald and Wells Fargo raised targets (to $800), with Cantor keeping an “overweight” view — reinforcing industrywide upgrades following the quarter. Benzinga
• Positive Sentiment: Regeneron highlighted EYLEA HD Phase 3 presentations at Angiogenesis 2026 (final 64‑week QUASAR and full ELARA results), which support the drug’s clinical profile and could underpin retinal franchise growth. EYLEA HD Presentations
• Positive Sentiment: Investors are digesting the company’s upbeat Q4 report (EPS and revenue beats) and accompanying earnings call commentary that boosted near‑term visibility. Q4 Earnings Transcript
• Neutral Sentiment: Morgan Stanley nudged its target to $769 but kept an “equal weight” rating — a modest adjustment that suggests limited conviction for sizable near‑term upside. TickerReport
• Neutral Sentiment: Truist trimmed its target slightly (to $818) but maintained a “buy,” reflecting minor calibration rather than a change in long‑term view. TickerReport
• Neutral Sentiment: Market commentary and pieces on Regeneron’s pipeline vs. valuation highlight a valuation gap and focus investors on execution of key pipeline catalysts over the next 12–24 months. Yahoo Finance

Insiders Place Their Bets

In other news, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 46.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on REGN. Oppenheimer reiterated an “outperform” rating and issued a $865.00 price target (up previously from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday. Cantor Fitzgerald upped their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the company an “overweight” rating in a report on Monday. JPMorgan Chase & Co. increased their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research report on Monday. UBS Group lifted their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Finally, Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 8th. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $799.74.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $755.02 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.77 and a quick ratio of 4.22. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The stock has a market capitalization of $79.35 billion, a PE ratio of 18.17, a P/E/G ratio of 1.92 and a beta of 0.40. The business has a fifty day moving average price of $758.27 and a two-hundred day moving average price of $652.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the business posted $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue was up 2.5% compared to the same quarter last year. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.47%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.